Protocol Ledger

NCT06593392 · Phase II · RECRUITING

Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus

Interventional Phase II clinical trial protocol NCT06593392 sponsored by Vifor Fresenius Medical Care Renal Pharma in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-08-04 Enrollment: 18 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06593392
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)18 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06593392
Protocol FieldVerified Registry Value
NCT IdentifierNCT06593392
Consolidated Lead SponsorVifor Fresenius Medical Care Renal Pharma
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment18 participants (ESTIMATED)
Registered Start Date2026-08-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06593392
Hospital Research SiteLocationSite Profile
The First Affiliated Hospital, Sun-Yat Sen UniversityGuangzhou, ChinaOpen Hospital Dossier ->
Shaare Zedek Medical CenterJerusalem, IsraelOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI